Data Sheet (Cat.No.TMAC-00388)

TargetMol

Anti-BCL10 Antibody (4H852)

Product Details

Ig Type:	IgG
Reactivity:	Human
Conjugation:	Unconjugated
Molecular Weight:	Theoretical: 31 kDa.
Clone:	4H852
Purification:	ProA affinity purified

Applications

Application:	ICC/IF,IHC,IP,WB
Recommended	WB: 1:1000; IHC: 1:50-200; ICC/IF: 1:50-200

Properties

Stability & Storage:	Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein
Uniprot ID:	O95999
Synonyms:	Cellular-E10 (c-E10);CARD-containing molecule enhancing NF-kappa-B;B-cell lymphoma/leukemia 10;Bcl10;B-cell CLL/lymphoma 10 (Bcl-10);Mammalian CARD-containing adapter molecule E10 (mE10);CLAP;CED-3/ICH-1 prodomain homologous E10-like regulator (CIPER);CIPER;Cellular homolog of vCARMEN (cCARMEN);CARD-like apoptotic protein (hCLAP)

Research Background

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene and, like E10, it contains an N-terminal caspase recruitment domain (CARD). Expression of Bcl10 has been shown to induce NFκB activation in a NIK-dependent pathway, and research indicates that the CARD domain is essential for this activation; although in a separate study, Bcl10 by itself did not induce JNK or NFκB activation. Overexpression of Bcl10 has been shown to induce apoptosis in a manner dependent on CARD-mediated oligomerization. Bcl10 has also been shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481